TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

Executive Summary

• TempraMed Technologies Ltd. has expanded its distribution agreement with McKesson Medical-Surgical (MMS) to include the full portfolio of its temperature-controlled medication solutions across North America.
• The partnership grants TempraMed access to MMS’s extensive B2B network, including physician offices, ambulatory surgery centers, and home health organizations, significantly broadening its commercial reach beyond retail pharmacies.
• The agreement facilitates deeper integration into the U.S. healthcare marketplace and aims to accelerate the adoption of TempraMed’s proprietary thermal protection solutions in non-acute care settings.

Key Details

• Parties Involved: TempraMed Technologies Ltd. (CSE: VIVI) and McKesson Medical-Surgical (MMS).
• Agreement Date: June 23, 2026.
• Scope of Distribution: Full portfolio distribution across North America, including all TempraMed products: VIVI Cap®, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™.
• Distribution Channels:
  • McKesson Medical-Surgical sales and distribution network.
  • Simply Medical, LLC (an MMS affiliate).
  • B2B2C partners.
  • Leading platforms such as Optum Now.
• Target Customer Base: Access to a diversified network of healthcare providers, specifically:
  • Physician offices
  • Ambulatory surgery centers
  • Long-term care facilities
  • Home health organizations
• Marketplace Integration: Integration into McKesson Medical-Surgical's marketplace, which aggregates approximately 270,000 SKUs and serves a nationwide customer base.
• Strategic Impact: The deal supports TempraMed’s transition toward a diversified revenue model by complementing its existing retail pharmacy footprint with scalable B2B distribution channels.
• Agreement Type: Non-exclusive distribution arrangement.

Notable Quotes

• Ron Nagar, CEO of TempraMed: "Our relationship with McKesson Medical-Surgical represents an important step in advancing our North American commercial strategy. Through this distribution arrangement, TempraMed expects to improve access to its temperature management solutions across a broader range of non-acute care providers and healthcare channels."
• Ron Nagar, CEO of TempraMed: "By making our full portfolio available through McKesson Medical-Surgical's distribution network, we aim to simplify product availability for healthcare professionals and patients managing temperature-sensitive medications. We believe this expanded reach will support broader market awareness and facilitate future commercial growth."